SOLICITATION NOTICE
66 -- Zeiss AxioObserver Z1 Microscope
- Notice Date
- 5/24/2007
- Notice Type
- Solicitation Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70063-NG
- Response Due
- 6/4/2007
- Archive Date
- 6/19/2007
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis for the purchase of a Zeiss AxioObserver Z1 Microscope; AxioObserver Optics; AxioObserver Fluorescence and; AxioObserver Incubation with Carl Zeiss MicroImaging, Once Zeiss Drive; Thornwood, New York, 10594. This acquisition will be conducted under the procedures for acquiring commercial items authorized in FAR Part 12 and under the authority to use simplified procedures for commercial requirements as provided in FAR 13.501. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. The salient characteristics apply to the Zeiss AxioObserver Z1 Microscope, AxioObserver Optics; AxioObserver Fluorescence and; AxioObserver Incubation instruments: Microscope Dimensions: Height 646 mm or 26 inches, Width 396mm or 16 inches, Length 613mm or 25 inches. Incubator Height 646 mm or 26 inches; width to 631mm to 26 inches, Length 613mm or 25 inches. AxioObserver Stand and Accessories: - TFT touch screen to visualize present working conditions on the microscope; - Docking Station for TFT Touch screen with Z-Focus control and x-y guide control of motorized Can-Bus; - Ergonomically and convenient placement of functional buttons - Motorized Z-focus with a step size of 10nm; - Improved Aquastop II (= patented water deflection/collection system) to better fit motorized and manual nosepieces; - Contrastmanager to automatically select the preset optimal contrast conditions per objective; - Motorized Can-Bus Stage with removable x-y guide; - Ability to insert an Apotome and do structural sectioning to eliminate background fluorescence. AxioObserver Optics: - DIC with an MgF2 plate to ensure homogeneity and precise pixel recognition in Fluorescence and DIC (no pixel shift). AxioObserver Fluorescence: - Fluorescence Beampath: Apochromatic correction where red, green and blue all image in the same plane; - Exchange of Push & Click Fluorescent cubes without taking the whole revolver out. AxioObserver Incubation: - Sensor technology PT100 - allows temperature sensor in the vicinity of the cell; - Control units are stackable; - Control units have markedly reduced temperature and concentration fluctuations; - Micromanipulation in CO2 environment ensures best physiological conditions for specimen; - Long term Incubator XL S1, more space inside for easier handling; in addition allows for TIRF and LSM laser safety. Justification: The NCI is interested in the genetic changes that define metastasis. The Carl Zeiss microscope will allow us to visualize changes in motility in vitro and assessment of tissue samples ex vivo, two elements that are crucial in monitoring the changes that allow for metastasis. The Zeiss AxioObserver Z1 microscope has the capability to go beyond the limits of the fluorescent microscope currently being used by the NCI. Carl Zeiss MicroImaging, Inc. is the only source known to the NCI that can provide the salient characteristics required of a microscope that can aid the NCI with its research; investigates genetic changes that define metastasis and signal transduction pathway for sarcoma cells survival and studies the role of oncogenes, growth factors, growth factor receptors, and downstream effector molecules in activation and proliferation. Benefit The Zeiss AxioObserver Z1 will allow NCI to image and record real time data of single cells in response to genetic modification or chemical agents. Currently the only option is to take images of cells before and after treatment, without the ability to monitor what happens to the cells during treatment. In addition, the visualization of tumor cells in live small animals is currently not possible. The inverted format of the microscope will allow NCI to place a small animal on the microscope for direct visualization. This will allow NCI to test the ability of drugs to destroy cancer cells. The drugs that we identify can then be used in treatment of cancer in humans. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM ET on June 4, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Malinda Holdcraft, Contract Specialist at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-70063-NG on all correspondence.
- Record
- SN01302312-W 20070526/070524220529 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |